Associated Papers
Impact of CSF3R Mutations on Leukemic Transformation in Severe Congenital Neutropenia: A Retrospective Analysis From the Italian Neutropenia Registry.
Pegoraro F et al.
American Journal of Hematology, 2026
Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemia.
Sommer C et al.
Scientific Reports, 2025
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A et al.
Journal of Hematology & Oncology, 2024
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Hirsch P et al.
Blood Cancer Journal, 2024
Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis.
Naumann N et al.
Cancers, 2024
Case report: Granulocyte-macrophage colony-stimulating factor sargramostim did not rescue the neutrophil phenotype in two patients with JAGN1-mutant severe congenital neutropenia.
Farmand S et al.
Frontiers in Immunology, 2024
Shwachman-Diamond syndromes: clinical, genetic, and biochemical insights from the rare variants.
Kawashima N et al.
Haematologica, 2023
A novel colony stimulating factor 3 receptor activating mutation identified in a patient with chronic neutrophilic leukemia.
Maniaci BN et al.
Haematologica, 2023
SPINK2 Protein Expression Is an Independent Adverse Prognostic Marker in AML and Is Potentially Implicated in the Regulation of Ferroptosis and Immune Response.
Pitts HA et al.
International Journal of Molecular Sciences, 2023
Chronic neutrophilic leukemia associated with thrombocytosis and a CSF3R Q781* nonsense mutation.
Abdulbaki R et al.
International Journal of Laboratory Hematology, 2023
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G et al.
Blood Advances, 2023
iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia.
Dannenmann B et al.
Cell Stem Cell, 2021
RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
Kim T et al.
Scientific Reports, 2020
Ultra-Sensitive CSF3R Deep Sequencing in Patients With Severe Congenital Neutropenia.
Klimiankou M et al.
Frontiers in Immunology, 2019
Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer Predisposition.
MacFarland SP et al.
Jco Precision Oncology, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Rothenberg-Thurley M et al.
Leukemia, 2018
Identification of novel MECOM gene fusion and personalized therapeutic targets through integrative clinical sequencing in secondary acute myeloid leukemia in a patient with severe congenital neutropenia: a case report and literature review.
Connelly JA et al.
Cold Spring Harbor Molecular Case Studies, 2018
Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations.
Zhang H et al.
Leukemia, 2017
Enhanced MAPK signaling is essential for CSF3R-induced leukemia.
Rohrabaugh S et al.
Leukemia, 2017
Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
Lavallée VP et al.
Blood, 2016
Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.
Maxson JE et al.
The Journal of Biological Chemistry, 2014
Granulocyte colony-stimulating factor receptor mutations in myeloid malignancy.
Liongue C et al.
Frontiers in Oncology, 2014
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Maxson JE et al.
The New England Journal of Medicine, 2013
Hematopoietic stem cell transplantation in severe congenital neutropenia.
Carlsson G et al.
Pediatric Blood & Cancer, 2011